In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research
This Special Issue published one editorial, eight articles and four reviews from approximately one hundred authors. It aimed to provide cutting-edge research on pre-clinical development and the clinical translation of radiopharmaceuticals within the molecular imaging community. The Special Issue cov...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_100794 | ||
| 005 | 20230623 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230623s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7390-8 | ||
| 020 | |a 9783036573915 | ||
| 020 | |a 9783036573908 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7390-8 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Yue, Xuyi |4 edt | |
| 700 | 1 | |a Yue, Xuyi |4 oth | |
| 245 | 1 | 0 | |a In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (220 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This Special Issue published one editorial, eight articles and four reviews from approximately one hundred authors. It aimed to provide cutting-edge research on pre-clinical development and the clinical translation of radiopharmaceuticals within the molecular imaging community. The Special Issue covered radioligand development, existing radiotracer optimization, imaging agent evaluation in animal models, the clinical production of radiopharmaceuticals, and investigative research on the use of molecular imaging probes in human subjects. We appreciate all the authors' significant contributions to this Special Issue and hope the readers will enjoy the content. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a nanoparticle | ||
| 653 | |a multimodal imaging | ||
| 653 | |a photoacoustic | ||
| 653 | |a heterobivalent peptide | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a amyloid-beta | ||
| 653 | |a animal model | ||
| 653 | |a astrocyte | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a imaging | ||
| 653 | |a metabolism | ||
| 653 | |a microglia | ||
| 653 | |a neuroinflammation | ||
| 653 | |a neurotransmitter receptors | ||
| 653 | |a positron emission tomography | ||
| 653 | |a synaptic density | ||
| 653 | |a vascular imaging | ||
| 653 | |a FDG | ||
| 653 | |a PET/CT | ||
| 653 | |a microvasculature imaging | ||
| 653 | |a ABC-transporter | ||
| 653 | |a drug-induced liver injury | ||
| 653 | |a hepatotoxicity | ||
| 653 | |a organic anion-transporting polypeptide | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a liver function | ||
| 653 | |a SLC-transporter | ||
| 653 | |a V/Q PET/CT | ||
| 653 | |a [68Ga]Ga-MAA | ||
| 653 | |a 68Ga-labelled carbon nanoparticles | ||
| 653 | |a glioblastoma | ||
| 653 | |a fluorescence guided surgery | ||
| 653 | |a 5-ALA | ||
| 653 | |a fluorescein | ||
| 653 | |a NIR-AZA | ||
| 653 | |a magnetic resonance imaging | ||
| 653 | |a high resolution | ||
| 653 | |a hybrid imaging | ||
| 653 | |a psychiatric disorders | ||
| 653 | |a extracellular vesicles (EVs) | ||
| 653 | |a umbilical cord mesenchymal stem cell (UCMSC) | ||
| 653 | |a diabetes | ||
| 653 | |a I-124 | ||
| 653 | |a positron emission tomography (PET) | ||
| 653 | |a intravenous (I.V.) administration | ||
| 653 | |a intra-arterial (I.A.) administration | ||
| 653 | |a biodistribution | ||
| 653 | |a fluorine-18 | ||
| 653 | |a PET | ||
| 653 | |a oxime | ||
| 653 | |a PSMA | ||
| 653 | |a lipophilicity | ||
| 653 | |a radiometals | ||
| 653 | |a copper-61 | ||
| 653 | |a liquid targets | ||
| 653 | |a post-processing | ||
| 653 | |a [61Cu]Cu-DOTA-NOC | ||
| 653 | |a [61Cu]Cu-DOTA-TOC | ||
| 653 | |a [61Cu]Cu-DOTA-TATE | ||
| 653 | |a FAP | ||
| 653 | |a 99mTc-FAP inhibitor | ||
| 653 | |a 99mTc-labeled iFAP | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a SPECT | ||
| 653 | |a GluN1/2B receptors | ||
| 653 | |a NMDA | ||
| 653 | |a [3H]ifenprodil | ||
| 653 | |a σ1 and σ2 receptors | ||
| 653 | |a receptor occupancy | ||
| 653 | |a PET imaging | ||
| 653 | |a drug development | ||
| 653 | |a neurodegenerative diseases | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7256 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/100794 |7 0 |z DOAB: description of the publication |